Loading company
Harrow, Inc.
HROW · Nasdaq · ·
Next earnings: November 9, 2026
$31.42-0.6%Sep 29 close
- 1M
- -15.7%
- 6M
- -5.6%
- 1Y
- -34.8%
- 5Y
- +227.6%
HROW · Nasdaq · ·
Next earnings: November 9, 2026
$31.42-0.6%Sep 29 close
Harrow, Inc. is scheduled to report next on November 9, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $70.7M | $63.7M | +10.85% |
| Profit | -$17.3M | $5M | -445.75% |
| Profit per share | -$0.46 | $0.13 | -453.85% |
| Free Cash Flow | -$10.2M | -$969K | -957.38% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Harrow, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Harrow, Inc. has no earnings call transcript available.